Spirox lands $19m Series B round

Spirox says it landed a nearly $19 million Series B round for its anti-nasal obstruction device.

Spirox said this week that it nailed down an $18.5 million Series B round to back development and commercialization of its device to treat patients with nasal obstructions.

Venrock and Aisling Capital led the round for Menlo Park, Calif.-based Spirox, with existing investors Aperture Venture Partners, Correlation Ventures and Western Technology Investment also participating.

Aisling Capital, Aperture Venture Partners, Correlation Ventures, Spirox, Venrock, Western Technology Investment

News Well, Funding Roundup, Otolaryngology/Ear, Nose & Throat (ENT), Venture Capital/Private Equity

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1d55kwZ